Site-Directed Engineering of Defined Chromosomal Sites for Recombinant Protein and Virus Expression - Site-directed engineering of defined chromosomal sites. - BioPharm International

ADVERTISEMENT

Site-Directed Engineering of Defined Chromosomal Sites for Recombinant Protein and Virus Expression
Site-directed engineering of defined chromosomal sites.


BioPharm International
Volume 22, Issue 7

REFERENCES

1. Bell AC, Felsenfeld G. Stopped at the border: boundaries and insulators. Curr Opin Genet Dev. 1999 Apr;9(2):191–8.

2. Festenstein R, Tolaini M, Corbella P, et al. Locus control region function and heterochromatin-induced position effect variegation. Science. 1996 Feb 23;271(5252):1123–5.

3. Schucht R, Coroadinha AS, Zanta-Boussif MA, et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther. 2006 Aug;14(2):285–92.

4. Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J Biotechnol. 2006 Jul 13;124(2):457–68.

5. Yarranton GT. Mammalian recombinant proteins: vectors and expression systems. Curr Opin Biotechnol. 1990 Dec;1(2):133–40.

6. Gama-Norton LR, P.; Sandhu U, Nehlsen K.; Schucht R, Hauser H, Wirth D. Defeating randomness—Targeted Integration as a Boost for Biotechnology. In: M. Al-Rubeai E, ed. Cell Engineering; in press.

7. Wirth D, Gama-Norton L, Riemer P, Sandhu U, Schucht R, Hauser H. Road to precision: recombinase-based targeting technologies for genome engineering. Curr Opin Biotechnol. 2007 Sep 26.

8. Baer A, Bode J. Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. Curr Opin Biotechnol. 2001 Oct;12(5):473–80.

9. Hauser H, Spitzer D, Verhoeyen E, Unsinger J, Wirth D. New approaches towards ex vivo and in vivo gene therapy. Cells Tissues Organs. 2000;167(2-3):75–80.

10. Verhoeyen E, Hauser H, Wirth D. Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. Hum Gene Ther. 2001 May 20;12(8):933–44.

11. Nehlsen K, Schucht R, Gama-Norton L, Krömer W, Baer A, Cayli A, Hauser H, Wirth, D. Recombinant protein expression by targeting pre-selected chromosomal loci. Submitted.

12. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007–an update. J Gene Med. 2007 Oct;9(10):833–42.

13. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 28;288(5466):669–72.

14. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. Apr 2006;12(4):401–9.

15. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet. Jun 14 2008;371(9629):2044–7.

16. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581–99.

17. Gama-Norton L, Herrmann S, Schucht R, Coroadinha A, Löw R, Alves P, Baum C, Schambach A, Hauser H, Wirth D. Retroviral vector performance upon integration in to defined chromosomal loci of modular packaging cell lines. Submitted.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here